Evidence map›Paper›PMID 26474456›Full record

ArticleOncotarget2015

MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer.

Mitchell E Menezes, Xue-Ning Shen, Swadesh K Das, Luni Emdad, Chunqing Guo, Fang Yuan, You-Jun Li, Michael C Archer, Eldad Zacksenhaus, Jolene J Windle and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Triterpenes ofInternational journal of molecular sciences · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Mitchell E MenezesDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Xue-Ning ShenDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Swadesh K DasDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Luni EmdadDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Chunqing GuoDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Fang YuanDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
You-Jun LiDepartment of Anatomy, Norman Bethune College of Medicine, Jilin University, Changchun, China.
Michael C ArcherDepartments of Medical Biophysics, University of Toronto, Ontario, Canada.
Eldad ZacksenhausDepartments of Medical Biophysics, University of Toronto, Ontario, Canada.
Jolene J WindleDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Mark A SublerDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Yaacov Ben-DavidDepartments of Medical Biophysics, University of Toronto, Ontario, Canada.
Devanand SarkarDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Xiang-Yang WangDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Paul B FisherDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
Virginia Commonwealth University · USUniversity of Toronto · CAFirst Bethune Hospital of Jilin University · CN

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
Mcl-1 in apoptosis and signal transduction: a structure/function approachR01CA168517 · NCI · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI PELLECCHIA, MAURIZIO · 2012 to 2024
$4.7M
MDA-7: Novel Cancer Therapeutic GeneR01CA097318 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B · 2002 to 2012
$2.8M
Interplay between tumor and microenvironment in bone metastasisR01CA259599 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B, WANG, XIANG-YANG SHAWN · 2021 to 2025
$2.3M
Host-tumor interactions and cancer relapse after radiation therapyR01CA175033 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI WANG, XIANG-YANG SHAWN · 2014 to 2018
$1.6M
Large Stress Proteins in Biology and MedicineR01CA154708 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI WANG, XIANG-YANG SHAWN · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA097318NCI NIH HHS R01 CA154708NCI NIH HHS R01 CA168517NCI NIH HHS R01 CA175033NCI NIH HHS R01 CA259599
6 · The paper itself

Abstract

Melanoma differentiation associated gene-7/Interleukin-24 (MDA-7/IL-24) is a novel member of the IL-10 gene family that selectively induces apoptosis and toxic autophagy in a broad spectrum of human cancers, including breast cancer, without harming normal cells or tissues. The ability to investigate the critical events underlying cancer initiation and progression, as well as the capacity to test the efficacy of novel therapeutics, has been significantly advanced by the development of genetically engineered mice (GEMs) that accurately recapitulate specific human cancers. We utilized three transgenic mouse models to better comprehend the in vivo role of MDA-7/IL-24 in breast cancer. Using the MMTV-PyMT spontaneous mammary tumor model, we confirmed that exogenously introducing MDA-7/IL-24 using a Cancer Terminator Virus caused a reduction in tumor burden and also produced an antitumor "bystander" effect. Next we performed xenograft studies in a newly created MMTV-MDA-7 transgenic model that over-expresses MDA-7/IL-24 in the mammary glands during pregnancy and lactation, and found that MDA-7/IL-24 overexpression delayed tumor growth following orthotopic injection of a murine PDX tumor cell line (mPDX) derived from a tumor formed in an MMTV-PyMT mouse. We also crossed the MMTV-MDA-7 line to MMTV-Erbb2 transgenic mice and found that MDA-7/IL-24 overexpression delayed the onset of mammary tumor development in this model of spontaneous mammary tumorigenesis as well. Finally, we assessed the role of MDA-7/IL-24 in immune regulation, which can potentially contribute to tumor suppression in vivo. Our findings provide further direct in vivo evidence for the role of MDA-7/IL-24 in tumor suppression in breast cancer in immune-competent transgenic mice.

Indexed as

Disease Models, AnimalGene Expression Regulation, NeoplasticAnimalsApoptosisCell DifferentiationCell Transformation, NeoplasticErb-b2 Receptor Tyrosine KinasesFemaleGenes, Tumor SuppressorHumansImmunoenzyme TechniquesInterleukin-24InterleukinsMammary Neoplasms, AnimalMammary Tumor Virus, MouseMiceErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesInterleukin-24Interleukinsmelanoma differentiation associated gene-7/interleukin-24 (MDA-7/IL-24)MMTV-MDA-7 miceMMTV-MDA-7/MMTV-Erbb2 miceMMTV-PyMT micetransgenic mice

Identifiers

PMID26474456
PMCPMC4741906
OpenAlexW1906911273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.